180 related articles for article (PubMed ID: 31514945)
1. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation.
Etminan M; Sodhi M; Ganjizadeh-Zavareh S; Carleton B; Kezouh A; Brophy JM
J Am Coll Cardiol; 2019 Sep; 74(11):1444-1450. PubMed ID: 31514945
[TBL] [Abstract][Full Text] [Related]
2. Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study.
Strange JE; Holt A; Blanche P; Gislason G; Torp-Pedersen C; Christensen DM; Hansen ML; Lamberts M; Schou M; Olesen JB; Fosbøl EL; Køber L; Rasmussen PV
Eur Heart J; 2021 Aug; 42(30):2899-2908. PubMed ID: 34245252
[TBL] [Abstract][Full Text] [Related]
3. Oral fluoroquinolones and risk of fibromyalgia.
Ganjizadeh-Zavareh S; Sodhi M; Spangehl T; Carleton B; Etminan M
Br J Clin Pharmacol; 2019 Jan; 85(1):236-239. PubMed ID: 30216492
[TBL] [Abstract][Full Text] [Related]
4. Effects of Fluoroquinolones on Outcomes of Patients With Aortic Dissection or Aneurysm.
Chen SW; Chan YH; Chien-Chia Wu V; Cheng YT; Chen DY; Lin CP; Hung KC; Chang SH; Chu PH; Chou AH
J Am Coll Cardiol; 2021 Apr; 77(15):1875-1887. PubMed ID: 33858624
[TBL] [Abstract][Full Text] [Related]
5. Serious cardiovascular adverse events with fluoroquinolones versus other antibiotics: A self-controlled case series analysis.
Aspinall SL; Sylvain NP; Zhao X; Zhang R; Dong D; Echevarria K; Glassman PA; Goetz MB; Miller DR; Cunningham FE
Pharmacol Res Perspect; 2020 Dec; 8(6):e00664. PubMed ID: 33047487
[TBL] [Abstract][Full Text] [Related]
6. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study.
Etminan M; Brophy JM; Samii A
Neurology; 2014 Sep; 83(14):1261-3. PubMed ID: 25150290
[TBL] [Abstract][Full Text] [Related]
7. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study.
Kuo SC; Chen YT; Lee YT; Fan NW; Chen SJ; Li SY; Liu CJ; Chen TL; Chen TJ; Fung CP
Clin Infect Dis; 2014 Jan; 58(2):197-203. PubMed ID: 24170197
[TBL] [Abstract][Full Text] [Related]
8. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
9. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study.
Sodhi M; Sheldon CA; Carleton B; Etminan M
Neurology; 2017 Aug; 89(8):792-795. PubMed ID: 28754842
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolones do not provide added risk of out-of-hospital cardiac arrest: a nationwide study.
Ellenardóttir V; Coronel R; Folke F; Halili A; Arulmurugananthavadivel A; Parveen S; Andersen MP; Schou M; Torp-Pedersen C; Gislason G; Eroglu TE
Open Heart; 2024 Jan; 11(1):. PubMed ID: 38216172
[TBL] [Abstract][Full Text] [Related]
11. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
[TBL] [Abstract][Full Text] [Related]
12. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone.
Lee CC; Lee MT; Chen YS; Lee SH; Chen YS; Chen SC; Chang SC
JAMA Intern Med; 2015 Nov; 175(11):1839-47. PubMed ID: 26436523
[TBL] [Abstract][Full Text] [Related]
13. Long-term Cardiovascular Adverse Events Induced by Fluoroquinolones: A Retrospective Case-control Study.
Algaidi SH; Alghamdi DI; Algheffari SG; Alzahrani RA; Thabit AK; Hafiz AM
J Cardiovasc Pharmacol; 2023 Nov; 82(5):400-406. PubMed ID: 37506675
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine.
Shively BK; Roldan CA; Gill EA; Najarian T; Loar SB
Circulation; 1999 Nov; 100(21):2161-7. PubMed ID: 10571975
[TBL] [Abstract][Full Text] [Related]
15. Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case-control study.
Son N; Choi E; Chung SY; Han SY; Kim B
BMC Cardiovasc Disord; 2022 Feb; 22(1):44. PubMed ID: 35152888
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones as a trigger for rupture of abdominal aortic aneurysm: A case-crossover analysis.
Lawaetz Kristensen K; Hallas J; Sanddal Lindholt J
Basic Clin Pharmacol Toxicol; 2021 Jul; 129(1):44-51. PubMed ID: 33887112
[TBL] [Abstract][Full Text] [Related]
17. Oral fluoroquinolone was linked to mitral and aortic regurgitation compared with amoxicillin or azithromycin.
Fralick M; Holbrook A
Ann Intern Med; 2020 Jan; 172(2):JC10. PubMed ID: 31958824
[No Abstract] [Full Text] [Related]
18. Risk of Intracranial Aneurysm and Dissection and Fluoroquinolone Use: A Case-Time-Control Study.
Maumus-Robert S; Debette S; Bérard X; Mansiaux Y; Tubert-Bitter P; Pariente A
Stroke; 2020 Mar; 51(3):994-997. PubMed ID: 31964291
[TBL] [Abstract][Full Text] [Related]
19. Association between oral fluoroquinolones and seizures: A self-controlled case series study.
Chui CS; Chan EW; Wong AY; Root A; Douglas IJ; Wong IC
Neurology; 2016 May; 86(18):1708-15. PubMed ID: 27053716
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study.
Tribouilloy C; Rusinaru D; Maréchaux S; Jeu A; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Ennezat PV; Garban T; Jobic Y
Circulation; 2012 Dec; 126(24):2852-8. PubMed ID: 23143159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
